SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the following investor conferences. Mr. Pascoe will provide an update on the European launch of Vitaros®, the Company's topical treatment for erectile dysfunction, as well as for Apricus' drug candidates fispemifene, for the treatment of men with secondary hypogonadism and RayVa™, for the treatment of patients with Raynaud's phenomenon.
|Taglich Brothers 12th Annual Investment Conference|
|Tuesday, May 5, 2015|
|Presentation at 10:10 a.m. Eastern Time|
|Le Parker Meridien, New York|
|SeeThruEquity 4th Annual Microcap Investor Conference|
|Thursday, May 28, 2015|
|Presentation at 10:00 a.m. Eastern Time|
|Convene Grand Central, New York|
A live audio webcast of the presentations can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 90 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus' lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus' marketing partners for Vitaros include Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus' second-generation room temperature Vitaros is under development. Apricus commenced a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon. Additionally, Apricus plans to initiate a Phase 2 trial for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms. Apricus is currently seeking a strategic partner to fund development of Femprox®, a product candidate for the treatment of female sexual interest/arousal disorder that completed an approximately 400-subject proof-of-concept study.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Institutional Investors: Angeli Kolhatkar email@example.com Arecia Advisors (917) 387-4770 Retail Investors: Chris Eddy, David Collins firstname.lastname@example.org Catalyst Global (212) 924-9800
Source:Apricus Biosciences, Inc.